National Institutes of Health: Breast Neoplasms trials

The registry lists 285 Breast Neoplasms studies with National Institutes of Health as lead sponsor. 21 are open to participants now and 80 have results posted.

Early Phase 1 3Phase 1 99Phase 2 115Phase 3 20No phase 69(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast CancerCompletedNCT00004888Phase 2Results posted
• Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to BonesWithdrawnNCT06982222Phase 1
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• Vaccine Response With NT-I7WithdrawnNCT04054752Phase 1
• Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingNCT04052555Phase 1
• A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerWithdrawnNCT03803761Phase 1/2
• Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast CancerWithdrawnNCT03377101Phase 2
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
• Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast CancerActive, not recruitingNCT02849496Phase 2
• Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnNCT02627430Phase 1
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...Active, not recruitingNCT02484404Phase 1/2
• Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTerminatedNCT02474173Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care TreatmentCompletedNCT02326857
• Breast Tissue Study of Breast Diseases Among Women in Hong KongCompletedNCT01885039
• Biomarkers for Breast Cancer Risk in African American WomenCompletedNCT01736306
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• GRN1005 for Brain Metastases From Breast or Lung CancerWithdrawnNCT01679743Phase 2
• The Ghana Breast Health StudyCompletedNCT01661023
• Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionCompletedNCT01638533Phase 1
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01624441Phase 1
• The Ultrasound Study of TamoxifenCompletedNCT01582074
• The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive IrradiationCompletedNCT01468883Phase 3
• Intestine Bacteria and Breast Cancer RiskCompletedNCT01461070
• AZD2281 Plus Carboplatin to Treat Breast and Ovarian CancerCompletedNCT01445418Phase 1
• 111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast CancerTerminatedNCT01445054Early Phase 1
• Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab OnlyCompletedNCT01434303Phase 1
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney DysfunctionActive, not recruitingNCT01366144Phase 1
• Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast CancerActive, not recruitingNCT01351909Phase 1
• MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast CancerCompletedNCT01344031Phase 1
• Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT01327781Phase 1
• Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast CancerTerminatedNCT01281163Phase 1
• Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT01281150Phase 1
• Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by SurgeryCompletedNCT01276496Phase 1
• Endoxifen in Adults With Hormone Receptor Positive Solid TumorsCompletedNCT01273168Phase 1
• MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast CancerCompletedNCT01263145Phase 1
• BRCA Mutations in LatinasCompletedNCT01251900
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
• AT13387 in Adults With Refractory Solid TumorsCompletedNCT01246102Phase 1
• Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast CancerCompletedNCT01245205Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedNCT01238133Phase 1
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
• RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast CancerTerminatedNCT01208441Phase 1
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast CancerTerminatedNCT01149356Phase 1
• Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast CancerCompletedNCT01145430Phase 1
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid TumorsCompletedNCT01131234Phase 1
• Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast CancerCompletedNCT01077453Phase 1
• RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By SurgeryTerminatedNCT01071564Phase 1
• Relationship of pAKT to Survival in Patients With Node-Positive Breast CancerCompletedNCT00965276
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung CancerTerminatedNCT00937482Phase 1
• Breast Stem Cells in Women at Average Risk and Increased Risk for Breast CancerCompletedNCT00923377
• An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated SkinCompletedNCT00923104
• Facilitating Web-based Patient Decision Support: Decision About Medication to Lower Breast Cancer RiskCompletedNCT00906321Not applicable
• Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous TherapyCompletedNCT00892736Phase 1
• Collection of Tissue Samples for Study of Multidrug ResistanceCompletedNCT00880503
• A Yoga and Wellness Program for Breast Cancer Survivors With Persistent FatigueCompletedNCT00727662Not applicable
• Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With AngiogenesisCompletedNCT00646555
• A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast CancerCompletedNCT00637481Phase 1
• Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)CompletedNCT00590785Phase 3
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT00576654Phase 1
• Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in WomenCompletedNCT00559039
• Defined Green Tea Catechin Extract in Treating Women With Hormone Receptor Negative Stage I-III Breast CancerCompletedNCT00516243Phase 1
• Breast Mammogram and Tissue StudyCompletedNCT00475761
• Risk Communication Within Mexican-American FamiliesCompletedNCT00469339
• Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By SurgeryTerminatedNCT00450879Phase 1
• Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Early Phase 1
• The Influence of Breast Cancer Risk and Risk Perception on Lifestyle Behaviors Among Women With a Family History: A Mixed Method ApproachCompletedNCT00393406
• AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By SurgeryCompletedNCT00348699Phase 1
• Pilot Study of Inflammatory Breast Cancer in Egypt and TunisiaCompletedNCT00344071
• Studying Normal Breast Tissue and Cancer RiskCompletedNCT00341692
• Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With GeneticsCompletedNCT00341458
• Breast Cancer, Breast Disease, and PesticidesCompletedNCT00341315
• Analysis of Data From the Women's Contraceptive and Reproductive Experiences (CARE) StudyCompletedNCT00341159
• Establishing an Inflammatory Breast Cancer RegistryCompletedNCT00340158
• Markers for Breast CancerCompletedNCT00339248
• AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast CancerCompletedNCT00310089Not applicable
• Insulin Resistance and Breast CancerCompletedNCT00304941
• Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous TrastuzumabCompletedNCT00301899Phase 2
• Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the LungCompletedNCT00301730Phase 1
• Sulindac in Preventing Breast Cancer in Women at High Risk for Breast CancerCompletedNCT00245024Phase 1
• Aromatase Inhibitor Clinical TrialStatus unknownNCT00228956
• Tamoxifen Pharmacogenetics and Clinical EffectsCompletedNCT00228930
• Effects of Soy Compounds on Breast Cancer, Prostate Cancer, and Bone HealthCompletedNCT00200824Phase 2
• Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer ScreeningCompletedNCT00131950Not applicable
• Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast CancerCompletedNCT00100750Phase 1/2
• Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain MetastasesCompletedNCT00098605Phase 2
• FR901228 in Treating Patients With Metastatic Breast CancerCompletedNCT00098397Phase 2
• Sorafenib in Treating Patients With Metastatic Breast CancerCompletedNCT00096434Phase 2
• 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast CancerTerminatedNCT00095888Phase 2
• Exercise in Women at Risk for Breast CancerCompletedNCT00092950Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Genetic and Protein Profiling in Normal and Cancerous Breast TissueCompletedNCT00083733
• Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast CancerCompletedNCT00080860Not applicable